ERIC BOERWINKLE to Double-Blind Method
This is a "connection" page, showing publications ERIC BOERWINKLE has written about Double-Blind Method.
Connection Strength
0.126
-
The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study. J Hum Hypertens. 2016 09; 30(9):549-54.
Score: 0.022
-
Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015 Jan 26; 4(1):e001521.
Score: 0.021
-
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study. PLoS One. 2012; 7(3):e34217.
Score: 0.017
-
Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. Stroke. 2011 Feb; 42(2):330-5.
Score: 0.016
-
Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. J Hypertens. 2010 Oct; 28(10):2076-83.
Score: 0.015
-
Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: the GenHAT study. Ann Hum Genet. 2007 Nov; 71(Pt 6):735-45.
Score: 0.012
-
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. Pharmacogenomics J. 2007 Apr; 7(2):112-22.
Score: 0.011
-
Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005 Jun 28; 111(25):3374-83.
Score: 0.011